De novo belatacept does not reduce the rate of skin cancer in renal transplant recipients compared to standard therapy (Supplemental Material)

Name: De novo belatacept does not reduce the rate of skin cancer in renal transplant recipients compared to standard therapy (Supplemental Material)
Creator: Olivia Jew
Published: 2024-05-14T06:48:17.966Z
Keywords: Dermatology, Skin Cancer, Organ Transplantation, Immunosuppression

Jew, Olivia; Liu, Winston; Stamey, Christopher; Kheterpal, Meenal; Myers, Sarah; Ellis, Matthew; Byrns, Jennifer; Wheless, Lee; Whitley, Melodi

doi:10.17632/r9r5pj2fzy.1

De novo belatacept does not reduce the rate of skin cancer in renal transplant recipients compared to standard therapy (Supplemental Material)

Published: 14 May 2024| Version 1 | DOI: 10.17632/r9r5pj2fzy.1

Contributors:

Olivia Jew, Winston Liu, Christopher Stamey, Meenal Kheterpal, Sarah Myers, Matthew Ellis, Jennifer Byrns, Lee Wheless, Melodi Whitley

Description

Supplemental data.

De novo belatacept does not reduce the rate of skin cancer in renal transplant recipients compared to standard therapy (Supplemental Material)

Description

Files

Categories

Licence